Gordon Carl L's Form 4 filing
Terns Pharmaceuticals, Inc.TERN · filed Aug 18, 2022
- Accession no.
- 0000947871-22-000910
- Filed
- Aug 18, 2022
- Trade date
- Aug 16, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $8.93M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gordon Carl LCIK 0001282930 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +2,470,200 | $2.42 | +$5,977,884 | 4,744,923 | Indirect | |
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +457,400 | $2.42 | +$1,106,908 | 1,973,881 | Indirect | |
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +762,400 | $2.42 | +$1,845,008 | 762,400 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +207,500 | –F5 | – | 207,500 | Indirect | |
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +38,450 | –F5 | – | 38,450 | Indirect | |
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +64,050 | –F5 | – | 64,050 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
Each Pre-Funded Warrant will be exercisable for one share of the Issuer's common stock at an exercise price per share of common stock equal to $0.0001 per share, each subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Issuer's common stock. Each Pre-Funded Warrant is exercisable from the date of issuance; provided that a holder will be prohibited from exercising a Pre-Funded Warrant if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock outstanding or 4.99% of the combined voting power of all of the Issuer's securities, in each case after giving effect to the exercise, which percentages may be changed at the holder's election to a higher or lower percentage not in excess of 19.99% upon 61 days' notice to the Issuer.
Referenced by the price of 3 transactions in Table II.